ArticleJournal of the advanced practitioner in oncology2023

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.

Rakesh Popat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.